Table II.

Development of CAR T-cells directed against GC tumor antigens

Tumor Antigen Target	Development Stage	CAR T- Cell Design	Clinical Trial	Reference
Claudin 18.2	Phase I Trial	Anti- Claudin 18.2 scFv/CD28/CD3	NCT03159819 NCT03874897	68, 69
MUC1	Phase I Trial	Anti- MUC1 scFv/CD28/OX40/CD3ζ	NCT04020575	71, 74
EpCAM	Phase I/II Trial	Anti-EpCAM scFv/ CD8α/ CD28/4–1BB/CD3ζ	NCT02725125	78
FOLR1	Phase I Trial	Anti-FOLR1 scFv/ CD28/CD3ζ	NCT03585764	80
Mesothelin	Phase I Trial	Anti-mesothelin scFv/ CD3ζ/4–1BB	NCT01897415 NCT04503980	82, 83, 84
CEA	Phase I Trial	Anti-CEA scFv/CD28/CD3ζ	NCT02349724	85
CA 72–4	Phase I Trial	Anti-CA 72–4 scFv/CD3ζ	—	88,89
NKG2D	Pre-Clinical	Anti-NKG2D scFv/CD3ζ	—	86, 87
ERBB2/HER2	Pre-Clinical	Anti-HER2 scFv/CD137/CD3ζ	—	81
B7H6	Pre-Clinical	Anti-B7H6 scFv/CD28/ CD3ζ	—	90